Norvasc Articles
Astra's Losec "World's No One Drug In 1998-2000"
16 December 1996
Zoloft Gets OCD Indication
4 November 1996
Net Income Rises 21% in 3rd Qtr At Pfizer
21 October 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
US OK For Pfizer's Norvasc In CHF
1 July 1996
1st-Qtr Sales Driven By New Products At Pfizer
22 April 1996
US Drug Price Restraint. Where Has It Gone?
4 March 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
FDA Panel Verdict On Calcium Blockers
5 February 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
All Change For Top Drugs In Year 2000: Lehman Bros
15 January 1996
Pfizer Presents Fertile Pipeline
6 November 1995
US 3rd Qrt Results: Strong Gains For Pfizer, Lilly
23 October 1995
Calcium Channel Blocker Debate Continues
11 September 1995
Calcium Blockers In Heart Failure: PRAISE Study
4 September 1995
JAMA Study Ups Debate Over Calcium Blockers
4 September 1995
Ciba Launches Lotrel In The USA
14 August 1995
Solid 2nd Qtr Earnings Growth For US Drugmakers
17 July 1995
Disease ManagementThe Way Forward
15 May 1995
Norvasc First Ca Blocker To Show Safety In CHF
27 March 1995
Calcium Channel Blockers Raise Heart Attack Risk?
20 March 1995
Strong Gains By US Firms In 2nd Quarter
1 August 1994
CIBA'S BENAZEPRIL/AMLODIPINE COMBO
20 June 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
NET PROFITS LEAP AT SUMITOMO PHARMA
7 March 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
JAPAN NEWS IN BRIEF
10 January 1994
NEW NHI LIST ADDITIONS IN JAPAN
20 December 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
ANALYSTS LOWER PFIZER RATING
5 July 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
MURPHY'S LAW PERVADES US DRUG STOCKS
17 May 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
PFIZER CONSIDERS PRICE CUTS
29 March 1993
PFIZER "COMMITTED" TO HEALTH CARE AND R&D
8 March 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
PFIZER RESOLVE ROW WITH FRENCH GOVT
9 November 1992
STOCK MARKET COMMENTARY: NEW YORK
4 May 1992
US FDA APPROVABLE LETTER TO PFIZER
4 May 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
